|Bid||1.27 x 300|
|Ask||1.35 x 3000|
|Day's Range||1.26 - 1.34|
|52 Week Range||1.02 - 3.70|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 11, 2017 - May 12, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.20|
Vical Incorporated (VICL) today announced that its Board of Directors plans to explore a range of strategic options to enhance shareholder value. The company has retained MTS Health Partners, L.P. as its financial advisor to assist in the strategic review process. Vical is currently developing its novel anti-fungal drug VL-2397, which is currently in a Phase 2 clinical trial, and, in addition, has a preclinical program focused on a novel approach to chronic HBV infections.
Vical Incorporated’s (NASDAQ:VICL): Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.Read More...
Vical Inc. said Monday a phase 2 trial of its treatment for genital herpes failed to meet its primary endpoint of annualized lesion recurrence rate. In a study of 261 healthy adults with herpes simplex virus type 2, aged 18 to 50, with a self-reported history of 4 to 9 recurrences a year, Vical said the annualized recurrence rate in the placebo group was "far less" than what was expected, meaning there was "significantly less power" to show a vaccine effect in the trial. "We are extremely disappointed with the outcome and based upon these results, we will be terminating the HSV-2 program," said Chief Executive Vijay Samant.
Vical Incorporated (VICL) today announced top-line results from a randomized, double-blind, placebo-controlled, Phase 2 clinical study of its therapeutic bivalent vaccine candidate for herpes simplex virus type 2 (HSV-2), the leading cause of recurrent genital herpes. The Phase 2 study was conducted in 261 healthy HSV-2 seropositive adults, 18 to 50 years of age, with a self-reported history of 4 to 9 recurrences per year. “We took careful measures to recruit patients with self-reported history of 4 to 9 recurrences annually.
Understanding Vical Incorporated’s (NASDAQ:VICL) performance as a company requires examining more than earnings from one point in time. Today I will take you through a basic sense check to gainRead More...
On a per-share basis, the San Diego-based company said it had a loss of 29 cents. The drug developer posted revenue of $716,000 in the period. The company's shares closed at $1.51. A year ago, they were ...
SAN DIEGO, May 03, 2018-- Vical Incorporated today reported financial results for the three months ended March 31, 2018. Net loss for the first quarter of 2018 was $6.3 million, or $0.29 per share, compared ...
NEW YORK, May 02, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of City ...
SAN DIEGO, April 26, 2018-- Vical Incorporated today announced that the company will report financial results for the three months ended March 31, 2018, before the opening of trading on Thursday, May 3, ...
NEW YORK, NY / ACCESSWIRE / March 15, 2018 / Vical Incorporated (NASDAQ: VICL ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 15, 2018, at 12:00 PM Eastern Time. ...
On a per-share basis, the San Diego-based company said it had a loss of 21 cents. The drug developer posted revenue of $4 million in the period. For the year, the company reported that its loss widened ...
WASHINGTON, Jan. 29, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of three new members to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. Motif Bio PLC (AIM/Nasdaq: MTFB), is a clinical-stage biopharmaceutical company focused on developing novel antibiotics to treat hospitalized patients with serious and life-threatening infections caused by multi-drug resistant (MDR) bacteria. Spero Therapeutics, Inc. (SPRO), is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for MDR bacterial infections.
TOKYO and SAN DIEGO, Jan. 22, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") and Vical Incorporated (VICL) announced today that ASP0113, an investigational DNA vaccine being developed for cytomegalovirus (CMV)-seropositive hematopoietic stem cell transplant (HSCT) recipients, did not meet its primary or secondary endpoints in the Phase 3 HELIOS clinical trial. "We are disappointed that the results did not demonstrate a significant improvement in overall survival and reduction in CMV end-organ disease," said Bernhardt G. Zeiher, president of Development, Astellas.
Zero-debt allows substantial financial flexibility, especially for small-cap companies like Vical Incorporated (NASDAQ:VICL), as the company does not have to adhere to strict debt covenants. However, it also faces higherRead More...